影响纤维素凝块形成的新型因素及其临床影响
Michał Ząbczyk1, Joanna Natorska2,3, Anetta Undas2,3
1Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland; Krakow Center for Medical Research and Technologies, St. John Paul II Hospital, Kraków, Poland. michal.zabczyk@uj.edu.pl
Polish archives of internal medicine
|November 6, 2024
概括
诸如XI/XIa因子升高和肠道透性标志物等新型因素有助于前血栓性纤维素凝块,增加中风和心脏病发作的风险. 了解这些纤维素凝块的特性是新疗法的关键.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 病理生理学 病理生理学
背景情况:
- 纤维素的形成对于血液静止和血栓形成至关重要.
- 纤维素凝块的结构和功能,特别是溶解能力,是复杂的,与血栓栓塞性疾病相关.
- 越来越多的证据将特定因素与改变的纤维素凝块特性联系起来.
研究的目的:
- 审查有助于原血栓性纤维素凝块性质的新型因素.
- 讨论与紧的纤维素网络和受损溶解相关的因素.
- 突出纤维素凝块特征在血栓栓塞事件中的临床相关性.
主要方法:
- 对影响纤维素凝块形成和性质的因素的最新数据的文献综述.
- 分析已识别的因素与血栓栓塞性疾病之间的关联.
- 检查针对这些因素的临床前和正在进行的研究.
主要成果:
- 提升的因子 (F) XI和FXIa,蛋白质碳化,中性粒细胞外细胞陷,循环的脂多糖化物,松素和抗血缺乏症都被讨论.
- 这些因素促进了紧的纤维素网络,其透性降低,溶解受损.
- 这些因素与缺血性中风,心肌梗塞,肺栓塞和心血管死亡有关.
结论:
- 讨论的因素与不利的纤维素凝块特征和增加的血栓栓塞风险有关.
- 纤维素凝块特性具有临床相关性,可能是未来治疗的目标.
- 对纤维素相关机制的进一步研究可能会导致预防血栓栓塞事件的新型治疗干预措施.
相关概念视频
Clot Retraction and Fibrinolysis
4.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
624
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
624
Extrinsic and Intrinsic Pathways of Hemostasis
5.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.8K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Disorders of Hemostasis
716
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
716
Coagulation
5.0K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
5.0K


